Countries in Europe, especially France, are highly affected due to the COVID-19 outbreak. EU and its member states are experiencing an economic and social crisis, in addition to the sanitary crisis; urges the Member States to consider the health impact of COVID-19 through a gender lens and to ensure the continuation of a full range of SRH services through the health systems in all circumstances, in line with international human rights standards; insists on countering any attempts to restrict SRHR during the pandemic and beyond; further calls on Member States to direct additional efforts and resources to rebuilding a health system which recognizes that SRHR are essential for the health and well-being of all persons. UNFPA’s projections from April 2020 stated that 47 million women in 114 low- and middle-income countries are expected to be unable to use modern contraceptives if the lockdown or supply chain disruptions continue for six months. The COVID-19 pandemic and the life-altering interruptions of migration have altered sexual priorities to the point where even defining appropriate sexual wellbeing timeframes is difficult. There may be resource constraints in monitoring that necessitates a multidimensional measure, as well as political opposition to elevating sexual well-being alongside risk-focused outcomes. Recognizing these issues, we present four ways in which sexual well-being is crucial to core functions of contemporary public health. The member states to ensure full access to contraception during the COVID-19 pandemic and, through joint efforts, to prevent disruptions in production and supply chains emphasize the examples of good practice such as accessible contraceptives for all women below a certain age group and/or teleconsultations in accessing contraceptives.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe sexual wellness market. The Europe sexual wellness market is expected to grow at a good CAGR during the forecast period.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 14,691.30 Million |
| Market Size by 2028 | US$ 22,432.32 Million |
| Global CAGR (2021 - 2028) | 6.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Pharmaceutical Product
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |